The efocus is faster absorption [Power / Sample Size]

posted by alejandro_jo1990 – Spain, 2022-09-02 20:57 (573 d 01:59 ago) – Posting: # 23263
Views: 2,182

❝ I am wondering why PK superiority? I am not getting if you do not prove faster onset of action with PD superiority, you can have advantage. Already the discussion for Tmax assessment (EMA PSG) is discussed in forum. Could you provide more details for not focusing on PD superiority?


Hi Diven thanks for the answer!
If you have the link to the thread reagarding the Tmax discussion, could you paste it here please? Regarding the issue, the want to demonstrate faster absorption not faster onset of action, therefore the whole discussion about if AUC, therapeutic ranges etc
BR
Alex

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
77 visitors (0 registered, 77 guests [including 10 identified bots]).
Forum time: 21:57 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5